磁共振引导放疗联合吉西他滨/白蛋白结合型紫杉醇化疗治疗不可手术胰腺癌:TITE-CRM Ⅰ期试验
这项单臂Ⅰ期研究采用时间-事件持续再评估法(TITE-CRM),在不可手术的临界可切除或局部晚期胰腺导管腺癌(BR/LA-PDAC)患者中,评估全剂量吉西他滨/白蛋白结合型紫杉醇联合磁共振引导消融性大分割放疗的最大耐受剂量。结果显示联合方案安全,最大耐受剂量为吉西他滨/白蛋白结合型紫杉醇(1000/100 mg/m2)联合 67.5 Gy/15 次,局部无进展生存率和远处无转移生存率令人鼓舞。
要点
- 30 例入组、26 例可评估,观察到 1 例剂量限制性毒性,DLT 率为 14.1%(3.3%-24.9%)。
- 最大耐受剂量为吉西他滨/白蛋白结合型紫杉醇(1000/100 mg/m2)联合 67.5 Gy/15 次。
- 中位总生存 14.5 个月,2 年局部无进展生存率 85%、远处无转移生存率 57%。
核心结论
- 全剂量吉西他滨/白蛋白结合型紫杉醇联合消融性磁共振引导放疗剂量在 BR/LA-PDAC 患者中是安全的,局部无进展生存率和远处无转移生存率令人鼓舞。
研究设计与样本
- 单臂Ⅰ期研究,采用时间-事件持续再评估法(TITE-CRM)进行剂量递增。
- 2015 年 3 月至 2019 年 2 月入组 30 例 BR/LA-PDAC 患者,26 例可评估(2 例放疗前进展,1 例计划阶段判定不适合放疗,1 例撤回知情同意)。
- 患者先接受吉西他滨/白蛋白结合型紫杉醇(1000/125 mg/m2)1 个周期,随后同步化疗联合放疗。
- 同步阶段吉西他滨/白蛋白结合型紫杉醇与放疗剂量按 TITE-CRM 递增:从 40 至 45 Gy/25 次联合化疗(600-800/75 mg/m2)递增至 60 至 67.5 Gy/15 次联合吉西他滨/白蛋白结合型紫杉醇(1000/100 mg/m2)。
- 主要终点为放疗的最大耐受剂量,以 60 天剂量限制性毒性(DLT)定义;DLT 为治疗相关 G5、G4 血液学毒性或需住院超过 3 天的 G3 胃肠道毒性。
主要发现
- 观察到 1 例 DLT,DLT 率为 14.1%(3.3%-24.9%)。
- 最大耐受剂量为吉西他滨/白蛋白结合型紫杉醇(1000/100 mg/m2)联合 67.5 Gy/15 次。
- 存活患者中位随访 40.6 个月时,中位总生存为 14.5 个月(95%CI 10.9-28.2 个月)。
- 东部肿瘤协作组评分为 0 的患者中位总生存为 34.1 个月(95%CI 13.6-54.1 个月),碳水化合物抗原 19-9 小于 90 的患者中位总生存为 43.0 个月(95%CI 8.0-未达到)。
- 2 年局部无进展生存率为 85%(95%CI 63%-94%),2 年远处无转移生存率为 57%(95%CI 34%-73%)。
关键数值与推荐
- DLT 定义:治疗相关 G5、G4 血液学毒性或需住院超过 3 天的 G3 胃肠道毒性。
- 最大耐受剂量:吉西他滨/白蛋白结合型紫杉醇(1000/100 mg/m2)联合 67.5 Gy/15 次。
- DLT 率 14.1%(3.3%-24.9%),观察到 1 例 DLT。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Ablative radiation therapy for borderline resectable or locally advanced pancreatic ductal adenocarcinoma (BR/LA-PDAC) may limit concurrent chemotherapy dosing and usually is only safely deliverable to tumors distant from gastrointestinal organs. Magnetic resonance guided radiation therapy may safely permit radiation and chemotherapy dose escalation. METHODS AND MATERIALS: We conducted a single-arm phase I study to determine the maximum tolerated dose of ablative hypofractionated radiation with full-dose gemcitabine/nab-paclitaxel in patients with BR/LA-PDAC. Patients were treated with gemcitabine/nab-paclitaxel (1000/125 mg/m2) x 1c then concurrent gemcitabine/nab-paclitaxel and radiation. Gemcitabine/nab-paclitaxel and radiation doses were escalated per time-to-event continual reassessment method from 40 to 45 Gy 25 fxs with chemotherapy (600-800/75 mg/m2) to 60 to 67.5 Gy/15 fractions and concurrent gemcitabine/nab-paclitaxel (1000/100 mg/m2). The primary endpoint was maximum tolerated dose of radiation as defined by 60-day dose limiting toxicity (DLT). DLT was treatment-related G5, G4 hematologic, or G3 gastrointestinal requiring hospitalization >3 days. Secondary endpoints included resection rates, local progression free survival (LPFS), distant metastasis free survival (DMFS), and overall survival (OS). RESULTS: Thirty patients enrolled (March 2015-February 2019), with 26 evaluable patients (2 progressed before radiation, 1 was determined ineligible for radiation during planning, 1 withdrew consent). One DLT was observed. The DLT rate was 14.1% (3.3%-24.9%) with a maximum tolerated dose of gemcitabine/nab-paclitaxel (1000/100 mg/m2) and 67.5 Gy/15 fractions. At a median follow-up of 40.6 months for living patients the median OS was 14.5 months (95% confidence interval [CI], 10.9-28.2 months). The median OS for patients with Eastern Collaborative Oncology Group 0 and carbohydrate antigen 19-9 <90 were 34.1 (95% CI, 13.6-54.1) and 43.0 (95% CI, 8.0-not reached) months, respectively. Two-year LPFS and DMFS were 85% (95% CI, 63%-94%) and 57% (95% CI, 34%-73%), respectively. CONCLUSIONS: Full-dose gemcitabine/nab-paclitaxel with ablative magnetic resonance guided radiation therapy dosing is safe in patients with BR/LA-PDAC, with promising LPFS and DMFS.
引用
- Kim H, Olsen JR, Green OL, et al. MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial. Int J Radiat Oncol Biol Phys. 2022. PMID: 35878713. doi:10.1016/j.ijrobp.2022.07.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。